KEYTRUDA® (pembrolizumab) and PADCEV™ (enfortumab vedotin-ejfv), a novel combination of two cancer medications, have been demonstrated to dramatically increase survival rates in patients with muscle-invasive bladder cancer who are not candidates for cisplatin-based chemotherapy. A significant advancement in the management of this aggressive illness has been made with the announcement by Pfizer and Astellas of the Phase 3 EV-303 clinical trial’s encouraging results.
Unprecedented Survival Benefit
In comparison to surgery alone, the EV-303 trial showed that the combination of PADCEV and KEYTRUDA, when given both before and after bladder removal surgery (cystectomy), improved event-free survival (EFS) and overall survival (OS) in a statistically significant and clinically meaningful way. For the first time in this patient population, a systemic treatment has demonstrated such a substantial survival benefit.
Read More: PADCEV-KEYTRUDA Duo Delivers First-Ever Survival Breakthrough for High-Risk Bladder Cancer Patients
For decades, patients with muscle-invasive bladder cancer who are ineligible for cisplatin treatment have faced limited treatment options, often relying on surgery alone. The groundbreaking benefits seen in the KEYNOTE-905/EV-303 trial at this early interim analysis position the pembrolizumab and enfortumab vedotin combination to fundamentally change the way we approach the treatment of patients with this disease.
Christof Vulsteke
Key Findings from the EV-303 Trial
Patients with muscle-invasive bladder cancer who were not eligible for cisplatin-based chemotherapy were recruited for the EV-303 trial, a worldwide, randomised, open-label study. EFS, the time interval between randomisation and the first instance of disease progression that precludes surgery or cancer recurrence following surgery, was the trial’s primary endpoint. In addition, the trial achieved the pathologic complete response (pCR) secondary endpoint, which is the absence of cancerous signs in tissue samples following treatment, and a key secondary endpoint of OS.
How the Combination Works
KEYTRUDA is a PD-1 inhibitor that aids the body’s immune system in combating cancer, while PADCEV is an antibody-drug conjugate (ADC) that targets and destroys cancer cells. The EV-303 trial’s better results are the result of a potent two-pronged attack on the cancer created by the combination of these two medications.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Safety Profile
The PADCEV and KEYTRUDA combination’s safety profile aligned with earlier research. Skin reactions and hyperglycemia were the most frequent adverse events. According to the press release, these side effects were usually tolerable.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
